Meningococcal Vaccines Market by Vaccine Serotype (MenACWY Vaccine, MenC Vaccine, MenB and BC Vaccine, MenAC Vaccine, MenA Vaccine); by Vaccine Type (Polysaccharide Meningococcal Vaccines, Subcapsular Meningococcal Vaccines, Conjugate Meningococcal Vaccines); by End User (Paediatric, Adult); by Region (North America, Europe, Asia-pacific, Latin America, Middle East Africa): Global Forecasts 2021 To 2027

Date : Oct 2021

|

Report ID : 482

|

Category : Biotechnology

|
Report Format:  PDF EXCEL PPT WORD

The Global Meningococcal vaccines market size was valued at USD 3.3 Bn by 2020 and is expected to reach USD 6.1 Bn by 2027, with a growing CAGR of 9.4 % during the forecast period.

Meningococcal disease is a bacterial infection caused by Neisseria meningitidis that is commonly known as meningococcus. This infection proliferates from less sever to the death. This infection affects the membrane of brain and eventually roll out towards spinal cord and blood. This infection is considered a deadly infections that spread through the exchange of respiratory and throat secretions such as air, spit or by intimate contact with infected person. This infection needs immediate diagnosis and monitoring.

Meningococcal Vaccine Market

Meningococcal vaccines market Dynamics

Meningococcal diseases have high fatality and frequency rate out of which 50% population remains untreated. Immediate antibiotic treatment is a first line measure to save lives and reduce complications. The highest disease burden is observed in sub-Saharan Africa that progress from Senegal in the west to the Ethiopia in the east.

According to the WHO (World Health Organization) survey 2021, 24 of the 26 countries have conducted meningitis prevention and awareness campaigns targeting 1-29 years old population that have high prevalence of infection. From vaccinated population, there is decline in incidence of NmA meningitis by more than 99%, no case has been reported since 2018.

The driving factors for global meningococcal vaccines market include increasing government initiatives for spreading awareness regarding early vaccination and growing research activities. Moreover, increasing public-private partnership for vaccine development, and increase in spending for healthcare further boost the growth of meningococcal vaccines market.

In addition to this, growing awareness regarding timely diagnosis & vaccination, rise in launch of meningococcal vaccines, and effectivity of vaccines to fight with meningococcal fuels the growth of meningococcal vaccines market. However, stringent government policies for vaccine approvals and high product recalls due to contamination hinders the growth of market.

 Global Meningococcal vaccines market Segmentation:

By Vaccine Serotype

  • MenACWY Vaccine
  • MenC Vaccine
  • MenB and BC Vaccine
  • MenAC Vaccine
  • MenA Vaccine

By Vaccine Type

  • Polysaccharide Meningococcal Vaccines
  • Subcapsular Meningococcal Vaccines
  • Conjugate Meningococcal Vaccines

By End User

  • Paediatric
  • Adult

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Based on vaccine serotype, MenACWY accounted for highest market share in 2020 and expected to increase more during the forecast period due to increase in demand for meningococcal vaccine and provide protection against four virus strains

Based on vaccine serotype, meningococcal vaccines market is segmented into MenACWY vaccine, MenC vaccine, MenB and BC vaccine,  MenAC vaccine, and MenA vaccine. MenACWY vaccine held the largest market share in 2020 and expected to increase more during forecast period due to increase in meningococcal infections and growing awareness regarding immunization.

Moreover, MenACWY vaccine provide protection against four strains of meningococcal bacteria such as A, C, W & Y, growing prevalence of bacterial infection in age group of 11-25 years, and rising research activities associated with meningococcal infection boost the growth of meningococcal vaccines market. However, MenA vaccine is expected to witness fastest market growth with highest CAGR during forecast period due to growing adoption in paediatric population.

Based on vaccine type, conjugate vaccine segment held the largest market share in 2020 and expected to increase more during forecast period due to its high immune response against bacterial capsular polysaccharides

Based on vaccine type, meningococcal vaccines market is segmented into polysaccharide meningococcal vaccines, subcapsular meningococcal vaccines and conjugate meningococcal vaccines. Conjugate meningococcal vaccine accounted for highest market share in 2020 due to its high defence mechanism against capsular polysaccharide bacteria.

Moreover, conjugate vaccine provides long lasting immunity against infection, increasing focus of pharmaceutical companies towards meningococcal conjugate vaccine products and growing incidence of meningococcal infection fuels the growth of meningococcal vaccines market. Strong conjugate vaccine pipeline and increase in R&D facilities further expected to grow the meningococcal vaccines market.

Based on end user, paediatric segment held maximum market share in 2020 due to increase in number of paediatric patients

Based on end user, meningococcal vaccines market is segmented into paediatric and adults. Paediatric segment accounted for the highest market share owing to increase in proneness of infection in this segment. Moreover, growing investments in paediatric products by key market companies and high infection liability in children below age 2 years boost the growth of meningococcal vaccines market. Increase in paediatric products availability and growing awareness regarding early vaccination amongst parents uplifts the growth of meningococcal vaccines market.

On the contrary, adults segment is expected to witness fastest growth with highest CAGR due to rising awareness regarding availability of meningococcal vaccines and adoption of national immunization programs leverage the growth of this segment in meningococcal vaccines market.

Based on geographical region, North America dominated the market in 2020 due to presence of large volume of key players and availability of high range of meningococcal vaccine products

Based on geographical region, North America dominated the meningococcal vaccines market due to presence of high volume of meningococcal infected patients in this region. Moreover, availability of strong government support for R&D, availability of major key players and growing investments for research activities further boost the growth of meningococcal vaccines market. Increasing rate of vaccination among paediatric population and improving healthcare infrastructure further uplifts the growth meningococcal vaccines market.

However, Asia-Pacific accounted for the largest market share in 2020 and expected to increase more during forecast period due to increase in awareness regarding early diagnosis and vaccination fuels the growth of meningococcal vaccines market in this region.

Company Profiles and Competitive Intelligence

The key players operating in the meningococcal vaccines market are:

  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Bio-Manguinhos
  • GlaxoSmithKline plc.
  • Serum Institute of India Ltd
  • Mitsubishi Tanabe Pharma Corporation
  • Bio-Med Pvt.Ltd
  • AstraZeneca
  • Walvax Biotechnology Co., Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  •  Chongqing Zhifei Biological Products Co., Ltd
  •  Hualan Biological Engineering Inc.
  • Pasteur
  • Incepta Pharmaceuticals Ltd.
  •  Bavarian Nordic
  •  Daiichi Sankyo Company Limited
  • Novavax
  • Emergent BioSolutions

The report also provides in-depth analysis of meningococcal vaccines market dynamics such as drivers, restraints, opportunities, and challenges

Drivers

  • Growing advances in medical technology
  • Growing aging population
  • Growing awareness regarding early diseases diagnosis

Restraints

  • Lack of sufficient epidemiological and surveillance data
  • Lack of advanced laboratory techniques such as PCR, for identification of bacteria

Opportunity

  • Emergence of key players in the market
  • Development in surveillance system
  • Production of affordable vaccines through product development partnership

Challenges  

  • Lack of availability of cost-effectiveness data
  • Unfavourable vaccine prioritization
  • High cost of vaccine

COVID-19 Impact on the Meningococcal vaccine market Analysis

Covid-19 has highly affected the industries in terms of growth, economy, health, and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety. Covid-19 has partially impacted the growth of meningococcal vaccines market. During covid-19 outbreak, major focus was given for the development of covid vaccine.

According to the survey, there was decline in number of patient registration for meningococcal infections. This tends to lower the growth for the development and manufacturing of meningococcal vaccines market. Moreover, pharmaceutical and biotechnological companies focused on the manufacturing of vaccine for covid infection due to heavy corona infection outbreak. This led to decrease in investment for the development of meningococcal vaccines.

The report also provides an in-depth analysis of key trends in meningococcal vaccines market

  • Emergence of advanced technology in vaccine development.
  • Exposure of hypervirulent meningococcal group W clone led countries to shift from monovalent meningococcal C to quadrivalent ACWY vaccines in national and international immunisation programmes.

The report also provides an in-depth analysis of recent news developments and investments

  • In April 2020, Sanofi received US-FDA approval for MenQuadfi meningococcal vaccine for prevention of meningococcal infections for patients below 2 years of age. This will help to expand the business of vaccine across the world.
  • In June 2021, Pfizer received US-FDA approval for PREVNAR 20™ for age group 18 years and above. The vaccine formulation contains capsular polysaccharide conjugates for 7 serotypes namely- 8, 10A, 11A, 12F, 15B, 22F and 33F that causes pneumococcal diseases and has high fatality rate. This product is expected to address the burden of pneumococcal diseases in adults, and this will help to provide global protection against pneumococcal serotypes.

The unique insights provided by this report also includes the following:

  • In-depth Value Chain Analysis
  • Opportunity Mapping
  • Sector Snapshot
  • Key Players Positioning Matrix
  • Regulatory Scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market Trends
  • Covid-19 Impact Analysis
  • Product Comparison
  • Pre & Post COVID 19 Impacts on Meningococcal vaccines market
  • Competitive Landscape
Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

  1.  Introduction
    1. Product Outline
    2. What is Meningococcal Vaccine Market?
    3. Analysis of Meningococcal Vaccine Market
    4. Covid -19 Impact
    5. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
    6. Technology Overview
  2. Regulatory Landscape for Meningococcal Vaccine Market
    1. Regulations and Standards
  3. Meningococcal Vaccine Market by Vaccine Serotype
    1. MenACWY Vaccine
    2. MenC Vaccine
    3.  MenB and BC Vaccine
    4. MenAC Vaccine
    5. MenA Vaccine
  4. Meningococcal Vaccine Market by Vaccine Type
    1. Polysaccharide Meningococcal Vaccines
    2. Subcapsular Meningococcal Vaccines
    3. Conjugate Meningococcal Vaccines
  5. Meningococcal Vaccine Market by End User
    1. Paediatric
    2. Adult
  6. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Netherlands
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Latin America
      1. Brazil
      2. Colombia
      3. Rest of Latin America
    5. Middle East Africa (MEA)
      1. GCC
      2. Rest of MEA
  7. Key Strategic Insights
  8. Market Analysis
    1. New Applications
    2. Emerging Technologies
    3. Opportunity Mapping
    4. Critical Success Factors
    5.  Consumer Preferences
  9. Key Market Trends / Recent Developments
  10. Competitive Scenario
    1.  Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product launches
    5.  Strength of product portfolio
    6.  Ranking of Key Players
    7. Presence of players by Geographies
  11. Key global players
    1. Pfizer Inc.
    2. Sanofi
    3. Novartis AG
    4. Bio-Manguinhos
    5. GlaxoSmithKline plc.
    6. Serum Institute of India Ltd
    7. Mitsubishi Tanabe Pharma Corporation
    8. Bio-Med Pvt.Ltd
    9. AstraZeneca
    10. Walvax Biotechnology Co., Ltd
    11. Johnson & Johnson
    12. Merck & Co., Inc.
    13.  Chongqing Zhifei Biological Products Co., Ltd
    14.  Hualan Biological Engineering Inc.
    15. Pasteur

Choose License
Buy Now
Why Choose AllTheResearch?
  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on “Quadrant Positioning” of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports. Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.


Quick Inquiry
Follow Us
Choose License
Buy Now